Maxim Group Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $20.00

Medicus Pharma (NASDAQ:MDCX) had its target price raised by stock analysts at Maxim Group from $10.00 to $20.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 335.73% from the stock’s previous close.

Several other research firms also recently issued reports on MDCX. D Boral Capital raised shares of Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of Medicus Pharma in a research report on Monday, April 28th.

Medicus Pharma Price Performance

MDCX stock opened at $4.59 on Thursday. Medicus Pharma has a 1 year low of $1.80 and a 1 year high of $6.00. The firm has a fifty day simple moving average of $3.65.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. Equities analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current year.

Institutional Trading of Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises about 1.3% of Interchange Capital Partners LLC’s holdings, making the stock its 15th biggest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.